Research · Sep 3, 2026
[DOC] Healthpeak Properties Thesis 2026: Physicians Realty Merger Tests Lab and Medical Office Integration
Healthpeak Properties, Inc. (NYSE: DOC; ticker change Healthpeak → DOC March 2024 post-Physicians Realty merger reflecting medical theme; rebranded to Healthpeak Properties 2019 from Healthcare Properties Trust) FY2025 revenue ~$2.7-2.9B (+5-8%) with adj. EPS ~$0.45-0.75 (FFO per share ~$1.85-2.10) reflecting continued post-March 2024 Physicians Realty Trust $21B merger integration (~$50M+ cost synergies achieved + ~50M+ sq ft medical office portfolio) + selected post-2024 Lab segment biopharma R&D cycle weakness (similar to ARE) + selected ~5-year continuous dividend track post-2020 reset under continued CEO Scott Brinker (~3-year tenure since November 2022). Leading life science + medical office + senior housing REIT focused on healthcare real estate. Founded 1985 as Healthcare Properties Trust + selected various rebrands and corporate transformations through ~40-year history; current Healthpeak Properties formed 2019 rebrand; merged with Physicians Realty Trust March 1, 2024 ~$21B aggregate (creating selected largest US healthcare REIT). Headquartered in Denver Colorado; ~340+ employees globally with ~$2.7-2.9B revenue. Three reporting segments: Lab (life science) ~50% revenue ($1.4B — post-2020 ~$5B+ life science portfolio acquisitions; ~$11M+ sq ft; San Francisco Bay Area ~40% + Boston ~30% + Research Triangle + selected), Outpatient Medical (medical office) ~30% ($0.85B — post-March 2024 Physicians Realty Trust merger contribution; ~50M+ sq ft hospital-affiliated MOB + ambulatory surgery centers + ~340 medical office buildings), CCRC (continuing care retirement communities) ~20% ($0.55-0.65B — senior housing operating partnership with selected operators). March 2024 Physicians Realty $21B merger integration: March 1, 2024 closing of Healthpeak + Physicians Realty Trust all-stock merger; Healthpeak ~67% post-merger ownership + Physicians Realty ~33%; Physicians Realty contributed ~$0.85B revenue + ~50M+ sq ft medical office portfolio + ~340 medical office buildings; ~$50M+ annualized cost synergies achieved by FY2025; ticker change Healthpeak → DOC reflecting medical/healthcare theme; FY2026 catalyst: continued integration + operating margin expansion via overhead consolidation. Lab segment biopharma R&D cycle: post-2020 ~$5B+ life science portfolio acquisitions; ~$11M+ sq ft (San Francisco Bay Area + Boston + Research Triangle); post-2024 biopharma R&D cycle weakness affecting Lab occupancy (~85-90% vs ~95%+ historical; similar to ARE); biotech tenant downsizing + lease non-renewals (~30-40% biopharma R&D budget tightening); FY2026 catalyst: continued biopharma cycle stabilization + Lab occupancy recovery toward ~88-92%. CEO Scott M. Brinker since November 2022 (succeeded Tom Herzog CEO 2019-November 2022 retired who led 2019 Healthpeak rebrand + post-2020 life science pivot; Brinker ex-Hines Securities chief operating officer + ~25-year career). Capital return: ~$1.20-1.24 annual dividend FY2025 (~5-year track post-2020 dividend reset); modest buybacks; investment-grade Baa1/BBB+ credit ratings; FCF $0.5-0.7B. FY2026 thesis: Physicians Realty integration + Lab biopharma cycle recovery + ~6-year dividend track + Outpatient Medical stability. Risks: Lab biopharma R&D cycle continued weakness, Physicians Realty integration disruption, major CCRC operator distress, interest rate severe.